Neuroenhancement of exposure therapy in anxiety disorders

AIMS Neuroscience

Volumn 2, Issue 3, 2015, Pages 123-138

  Hofmann, Stefan G ^a   Mundy, Elizabeth A ^a   Curtiss, Joshua ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Anxiety disorders; Cognitive behavioral therapy; Cognitive enhancer; D cycloserine; Exposure therapy; Extinction; Neuroenhancer

Indexed keywords

EID: 84970952908     PISSN: None     EISSN: 23737972     Source Type: Journal    
DOI: 10.3934/Neuroscience.2015.3.123     Document Type: Review

References (100)

1. Hofmann SG, Asnaani A, Vonk JJ, et al. (2012) The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognitive Ther Res 36: 427-440
2. Hofmann SG, Smits JA (2008) Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 69: 621-632
3. Hofmann SG, Otto MW, Pollack MH, et al. (2015) D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Anxiety Disorders: an Update. Curr Psychiatry Rep 17(1): 1-5
4. Hofmann SG (2008) Cognitive processes during fear acquisition and extinction in animals and humans: Implications for exposure therapy of anxiety disorders. Clin Psychol Rev 28: 199-210
5. Singewald N, Schmuckermair C, Whittle N, et al. (2015) Pharmacology of cognitive enhancers for exposure-based therapy for fear, anxiety, and trauma-related disorder. Pharmacol Ther 149:150-190
6. Hofmann SG, Meuret AE, Smits JA, et al. (2006) Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63: 298-304
7. Smits JA, Rosenfield D, Davis ML, et al. (2014) Yohimbine enhancement of exposure therapy for social anxiety disorder: A randomized controlled trial. Biol Psychiatry 75: 840-846
8. Davis M, Ressler K, Rothbaum BO, et al. (2006) Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60: 369-375
9. Richardson R, Ledgerwood L, Cranney J (2004) Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem 11: 510-516
10. Bouton ME, Vurbic D, Woods AM (2008) D-cycloserine facilitates context-specific fear extinction learning. Neurobiol Learn Mem 90: 504-510
11. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. (2004) Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61: 1136-1144
12. Otto MW, Tolin DF, Simon NM, et al. (2010) Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67: 365-370
13. Hofmann SG (2014) D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety 31: 175-177
14. Hofmann SG, Hüweler R, Mackillop J, et al. (2012) Effects of d-cycloserine on craving to alcohol cues in problem drinkers: Preliminary findings. Am J Drug Alcohol Abuse 38: 101-107
15. Lee JL, Milton AL, Everitt BJ (2006) Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci 26: 10051-10056
16. Hofmann SG, Smits JA, Rosenfield D, et al. (2013) D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry 170: 751-758
17. Smits JAJ, Rosenfield D, Otto MW, et al. (2013) D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiat Res 47: 1455-1461
18. Holmes A, Quirk GJ (2010) Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders-the case of yohimbine. Trends Pharmacol Sci 31: 2-7
19. Cain CK, Blouin AM, Barad M (2004). Adrenergic transmission facilitates extinction of conditional fear in mice. Learn Mem 11: 179-187
20. O'Carroll RE, Drysdale E, Cahill L, et al. (1999) Stimulation of the noradrenergic system enhances and blockade reduces memory for emotional material in man. Psychol Med 29: 1083-1088
21. Powers MB, Smits JAJ, Otto MW, et al. (2009) Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: A randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 23: 350-356
22. Lupien SJ, McEwen BS, Gunnar MR, et al. (2009) Effects of stress throughout the lifespan on the brain, behavior and cognition. Nat Rev Neurosci 10: 434-445
23. De Quervain DJF, Aerni A, Schelling G, et al. (2009) Glucocorticoids and the regulation of memory in health and disease. J Epidemiol commu H 30(3): 358-370
24. Roozendaal B, McGaugh JL (1997) Glucocorticoid receptor agonist and antagonist administration into the basolateral but not central amygdala modulates memory storage, Neurobiol Learn Mem 67: 176-179
25. Lupien SJ, Fiocco A, Wan N, et al. (2005) Stress hormones and human memory function across the lifespan. Psychoneuroendocrinol 30(3): 225-242
26. Otto MW, McHugh Rk, Kantak KM (2010) Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: Medication effects, glucocorticoids, and attenuated treatment outcomes. Clin Psychol 17(2): 91-103
27. Andreano JM, Cahill L (2006) Glucocorticoid release and memory consolidation in men and women. Psychol Sci 17(6): 466-470
28. Roozendaal B, Williams CL, McGaugh JL (1999) Glucocorticoid receptor activation in the rat nucleus of the solitary tract facilitates memory consolidation: Involvement of the basolateral amygdala. Eur J Neurosci 11(4): 1317-1323
29. Cai WH, Blundell J, Han J, et al. (2006) Postreactivation glucocorticoids impair recall of established fear memory. J Neurosci 26(37): 9560-9566
30. Pakdel R, Rashidy-Pour A (2007) Microinjections of the dopamine D2 receptor antagonist sulpiride into the medial prefrontal cortex attenuate glucocorticoid-induced impairment of long-term memory retrieval in rats. Neurobiol Learn Mem 87(3): 385-390
31. Barrett D, Gonzalez-Lima F (2004) Behavioral effects of metyrapone on Pavlovian extinction. Neurosci Lett 371(2-3): 91-96
32. Bohus B, Lissak K (1968) Adrenocortical hormones and avoidance behavior of rats. Int J Neuropharmacol 7(4): 301-306
33. Yang YL, Chao PK, Lu KT (2006) Systemic and intra-amygdala administration of glucocorticoid agonist and antagonist modulate extinction of conditioned fear. Neuropsychopharmacol 31(5): 912-924
34. Lass-Hennemann J, Michael T (2014) Endogenous cortisol levels influence exposure therapy in spider phobia. Behav Res Ther 60: 39-45
35. Soravia LM, Heinrichs M, Aerni A, et al. (2006) Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 103(14): 5585-5590
36. Soravia LM, Heinrichs M, Winzeler L, et al. (2014) Glucocorticoids enhance in vivo exposure-based therapy if spider phobia. Depress Anxiety 31: 429-435
37. De Quervain DJ, Bentz D, Michael T, et al. (2011) Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci USA 108(16): 6621-6625
38. Meuret AE, Trueba AF, Abelson JL, et al. (2015) High cortisol awakening response and cortisol levels moderate exposure-based psychotherapy success. Psychoneuroendocrinol 51: 331-340
39. Siegmund A, Koster L, Meves AM, et al. (2011) Stress hormones during flooding therapy and their relationship to therapy outcome in patients with panic disorder and agoraphobia. J Psychiatr Res 45(3): 339-346
40. Suris A, North C, Adinoff B, et al. (2010) Effects of exogenous glucocorticoid on combat-related PTSD symptoms. Ann Clin Psychiatry 22: 274-279
41. Aerni A, Traber R, Hock C, et al. (2004) Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 161(8): 1488-1490
42. Fries E, Hellhammer DH, Hellhammer J (2006) Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. Psychoneuroendocrinol 31(10): 1278-1288
43. Pomara N, Willoughby LM, Sidtis JJ, et al. (2005) Cortisol response to diazepam: Its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. Psychopharmacol 178(1): 1-8
44. Brown RM, Crane AM, Goldman PS (1979) Regional distribution of monoamines in the cerebral cortex and subcortical structures of rhesus monkey: concentrations and in vivo synthesis. Brain Res 168: 133-150
45. Goldman-Rakic PS (1991) Prefrontal cortical dysfunction in schizophrenia: the relevance of working memory. In: Psychopathology and the Brain, edited by B. Carroll, New York: Raven, 1-23
46. Sawaguchi T, Goldman-Rakic PS (1994) The role of D1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 71(2): 515-528
47. Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74(1): 1-58
48. Bromberg-Martin ES, Matsumoto M, Hikosaka O (2010) Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 68(5): 815-834
49. Nikolaus S, Antke C, Beu M, et al. (2010) Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders: Results from in vivo imaging studies. Rev Neurosci 21(2): 119-139
50. Olver JS, O'Keefe G, Jones GR, et al. (2009) Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. J Affect Disord 114(1-3): 321-326
51. De la Mora MP, Gallegos-Cari A, Arizmendi-Garcia Y, et al. (2010) Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis. Prog Neurobiol 90(2): 198-216
52. Koo MS, Kim EJ, Roh D, et al. (2010) Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Rev Neurother 10(2): 275-290
53. Insel TR (2010) The challenge of translation in social neuroscience: A review of oxytocin, vasopressin, and affiliative behavior. Neuron 65(6): 768-779
54. Kosfeld M, Heinrichs M, Zak PJ, et al. (2005) Oxytocin increases trust in humans. Nat 435(7042): 673-676
55. Meyer-Lindenberg A, Domes G, Kirsch P, et al. (2011). Oxytocin and vasopressin in the human brain: Social neuropeptides for translational medicine. Nat Rev Neurosci 12(9): 524-538
56. Frith CD (2008) Social Cognition. Philos Trans R Soc Biol Sci, 363: 2033-2039
57. Eisenberg N, Miller PA (1987) The relation of empathy to prosocial and related behaviors. Psycholog Bull, 101: 91-119
58. Perez-Rodriguez MM, Mahon K, Russo M, et al. (2015) Oxytocin and social cognition in affective and psychotic disorders. Eur Neuropsychopharmacol 25: 265-282
59. Zak PJ, Kurzban R & Matzner WT (2005) Oxytocin is associated with human trustworthiness. Horm Behav 48(5): 522-527
60. Grewen KM, Girdler SS, Amico J, et al. (2005) Effects of partner support on resting oxytocin, cortisol, norepinephrine, and blood pressure before and after warm partner contact. Psychosom Med 67(4): 531-538
61. Scantamburlo G, Hansenne M, Fuchs S, et al. (2007). Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinol 32(4): 407-410
62. Goldman M, Marlow-O'Connor M, Torres I, et al. (2008) Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res 98(1-3): 247-255
63. Green L, Fein D, Modahl C, et al. (2001) Oxytocin and autistic disorder: Alterations in peptide forms. Biol Psychiatry 50(8): 609-613
64. Cyranowski JM, Hofkens TL, Frank E, et al. (2008) Evidence of dysregulated peripheral oxytocin release among depressed women. Psychosom Med 70(9): 967-975
65. Taylor SE, Gonzaga GC, Klein LC, et al. (2006) Relation of oxytocin to psychological stress responses and hypothalamic-pituitary-adrenocortical axis activity in older women. Psychosom Med 68(2): 238-245
66. Hoge EA, Pollack MH, Kaufman RE, et al. (2008) Oxytocin levels in social anxiety disorder. CNS Neurosci Ther 14(3): 165-170
67. Born J, Lange T, Kern W, et al. (2002) Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci 5(6): 514-516
68. Mikolajczak M, Gross JJ, Lane A, et al. (2010) Oxytocin makes people trusting, not gullible. Psychol Sci 21(8): 1072-1074
69. Mikolajczak M, Pinon N, Lane A, et al. (2010) Oxytocin not only increases trust when money is at stake, but also when confidential information is in the balance. Biol Psychol 85(1): 182-184
70. Baumgartner T, Heinrichs M, Vonlanthen A, et al. (2008) Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58(4): 639-650
71. Hofmann S G, Fang A, Brager D N (in press). Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies.Psychiatry Res
72. Guastella AJ, Howard AL, Dadds MR, et al. (2009) A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinol 34(6): 917-923
73. MacDonald E, Dadds MR, Brennan JL, et al. (2011) A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinol 36(8): 1114-1126
74. Labuschagne I, Phan KL, Wood A, et al. (2010) Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacol 35(12): 2403-2413
75. Labuschagne I, Phan KL, Wood A, et al. (2012) Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol 15: 883-896
76. Fang A, Hoge E A, Heinrichs M, et al. (2014) Attachment Style Moderates the Effects of Oxytocin on Social Behaviors and Cognitions During Social Rejection: Applying an RDoC Framework to Social Anxiety. Clin Psychol Sci 2 (6):740-747
77. Minzenberg MJ, Carter CS (2008) Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacol 33(7): 1477-1502
78. Volkow ND, Fowler JS, Logan J, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301(11): 1148-1154
79. Madras BK, Xie Z, Lin Z, et al. (2006) Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319: 561-569
80. Hermant JF, Rambert FA, Duteil J (1991) Awakening properties of modafinil: Effect on nocturnal activity in monkeys (Macacamulatta) after acute and repeated administration. Psychopharmacol 103(1): 28-32
81. Kahbazi M, Ghoreishi A, Rahiminejad F, et al. (2009) A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 168(3): 234-237
82. Randall DC, Shneerson JM, Plaha KK, et al. (2003) Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol 18(3): 163-173
83. Wong YN, King SP, Simcoe D, et al. (1999) Open-label, single-dose pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects. J Clin Pharmacol 39(3): 281-288
84. Murphy HM, Ekstrand D, Tarchick M, et al. (2015) Modafinil as a cognitive enhancer of spatial working memory in rats. Physiol Behav 142: 126-130
85. Rasetti R, Mattay VS, Stankevich B, et al. (2010) Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacol 35(10): 2101-2109
86. Schwartz JR, Hirshkowitz M, Erman MK, et al. (2003) Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 124(6): 2192-2199
87. Zifko UA, Rupp M, Schwarz S, et al. (2002) Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249(8): 983-987
88. Balanza-Martinez V, Fries GR, Colpo GD, et al. (2011) Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Rev Neurotherapeutics 11: 1029-1047
89. Bloch MH, Qawasmi A (2011) Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 50: 991-1000
90. Cosci F, Abrams K, Schruers KRJ, et al. (2006) Effect of nicotine on 35% CO2-induced anxiety: A study in healthy volunteers. Nicotine Tob Res 8, 511-517
91. Gertsik L, Poland RE, Bresee C, et al. (2012) Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 32: 61-64
92. Lesperance FO, Frasure-Smith N, St-Andre E, et al. (2011) The efficacy of omega-3 supplementation for major depression: A randomized controlled trial. J Clin Psychiatry 72: 1054-1062
93. Masdrakis VG, Papakostas YG, Vaidakis N, et al. (2008) Caffeine challenge in patients with panic disorder: Baseline differences between those who panic and those who do not. Depress Anxiety 25, E72-E79
94. Mystkowski JL, Mineka S, Vernon LL, et al. (2003) Changes in caffeine states enhance return of fear in spider phobia. J Consult Clin Psychol 71: 243-250
95. Salin-Pascual RJ, Basanez-Villa E (2003) Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. Revista de Investigacion Clinica 55: 650-654
96. Culver NC, Vervliet B, Craske MG (2014). Compound Extinction Using the Rescorla-Wagner Model to Maximize Exposure Therapy Effects for Anxiety Disorders. Clin Psychol Sci 2167702614542103
97. McNamara RK, Carlson SE (2006) Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids 75: 329-349
98. Timonen M, Horrobin D, Jokelainen J, et al. (2004) Fish consumption and depression: The Northern Finland 1966 birth cohort study. J Affective Disord 82: 447-452
99. McNamara RK (2011) Omega-3 fatty acid deficiency: A preventable risk factor for schizophrenia? Schizophr Res 129: 215-216
100. Hofmann SG, Sawyer AT, Korte KJ, et al. (2009) Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther 2: 160-175